Organogenesis (ORGO) News Today $4.70 -0.52 (-9.96%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$4.73 +0.03 (+0.64%) As of 03/26/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Organogenesis (NASDAQ:ORGO) Shares Gap Up - Should You Buy?Organogenesis (NASDAQ:ORGO) Shares Gap Up - Here's What HappenedMarch 26 at 11:50 AM | marketbeat.comOrganogenesis (NASDAQ:ORGO) Stock Price Up 9.5% - Time to Buy?Organogenesis (NASDAQ:ORGO) Stock Price Up 9.5% - Here's What HappenedMarch 25 at 4:40 PM | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Stock Position Raised by Bank of New York Mellon CorpBank of New York Mellon Corp grew its position in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 35.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 418,820 shares of the company's stock after purchasinMarch 24 at 3:06 AM | marketbeat.comOrganogenesis (NASDAQ:ORGO) Trading Up 3.5% - What's Next?Organogenesis (NASDAQ:ORGO) Trading Up 3.5% - Still a Buy?March 19, 2025 | marketbeat.comOrganogenesis Holdings: Solid Finances Protect From Uncertain EnvironmentMarch 18, 2025 | seekingalpha.comHead-To-Head Analysis: Organogenesis (NASDAQ:ORGO) vs. OnKure Therapeutics (NASDAQ:OKUR)March 18, 2025 | americanbankingnews.comOrganogenesis (NASDAQ:ORGO) Trading Down 2.1% - What's Next?Organogenesis (NASDAQ:ORGO) Stock Price Down 2.1% - What's Next?March 15, 2025 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Director Sells $127,500.00 in StockOrganogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll sold 25,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. This represents a 13.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.March 7, 2025 | marketbeat.comInsider Selling: Organogenesis Holdings Inc. (NASDAQ:ORGO) Director Sells 25,000 Shares of StockMarch 7, 2025 | insidertrades.comOrganogenesis (NASDAQ:ORGO) Stock Price Up 9.1% After Analyst UpgradeOrganogenesis (NASDAQ:ORGO) Trading 9.1% Higher After Analyst UpgradeMarch 6, 2025 | marketbeat.comOrganogenesis (NASDAQ:ORGO) Price Target Raised to $6.00Morgan Stanley increased their price target on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research note on Wednesday.March 6, 2025 | marketbeat.comOrganogenesis (NASDAQ:ORGO) Stock Price Down 6.2% - Here's What HappenedOrganogenesis (NASDAQ:ORGO) Shares Down 6.2% - Time to Sell?March 5, 2025 | marketbeat.comMorgan Stanley Keeps Their Hold Rating on Organogenesis Holdings (ORGO)March 5, 2025 | markets.businessinsider.comOrganogenesis price target raised to $6 from $4 at Morgan StanleyMarch 5, 2025 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Organogenesis Holdings (ORGO)March 5, 2025 | markets.businessinsider.comCornerstone Investment Partners LLC Buys Shares of 50,502 Organogenesis Holdings Inc. (NASDAQ:ORGO)Cornerstone Investment Partners LLC purchased a new position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 50,502 shares of the company's stock,March 5, 2025 | marketbeat.comOrganogenesis (NASDAQ:ORGO) Shares Gap Down - Here's WhyOrganogenesis (NASDAQ:ORGO) Shares Gap Down - Time to Sell?March 3, 2025 | marketbeat.comOrganogenesis (NASDAQ:ORGO) Sets New 12-Month High - Should You Buy?Organogenesis (NASDAQ:ORGO) Hits New 1-Year High - Time to Buy?March 1, 2025 | marketbeat.comOrganogenesis Hldgs (NASDAQ:ORGO) Stock Quotes, Forecast and News SummaryMarch 1, 2025 | benzinga.comOrganogenesis (NASDAQ:ORGO) Issues Earnings ResultsOrganogenesis (NASDAQ:ORGO - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%.February 28, 2025 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | insidermonkey.comOrganogenesis price target raised to $7 from $6 at BTIGFebruary 28, 2025 | markets.businessinsider.comLake Street Remains a Buy on Organogenesis Holdings (ORGO)February 28, 2025 | markets.businessinsider.comOrganogenesis (ORGO) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comOrganogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comOrganogenesis stock surges on earnings beat, strong guidanceFebruary 27, 2025 | in.investing.comOrganogenesis sees FY25 revenue $480M-$535M, consensus $472.94MFebruary 27, 2025 | markets.businessinsider.comOrganogenesis stock jumps 17% on Q4 report, outlookFebruary 27, 2025 | msn.comOrganogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial ResultsFebruary 27, 2025 | globenewswire.comOrganogenesis (ORGO) Expected to Announce Earnings on ThursdayOrganogenesis (NASDAQ:ORGO) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=659383)February 20, 2025 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Shares Bought by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 107.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 205,943 shares of the company's stock after pJanuary 28, 2025 | marketbeat.comOrganogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025January 27, 2025 | globenewswire.comCantor Fitzgerald Estimates Organogenesis FY2025 EarningsOrganogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Organogenesis in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will postJanuary 23, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $9.44 Million Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)Assenagon Asset Management S.A. lifted its position in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 54.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,950,849 shares of the company's stock after acquiring an aJanuary 19, 2025 | marketbeat.comOrganogenesis Holdings Leads These 3 US Penny StocksJanuary 16, 2025 | uk.finance.yahoo.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Up 29.1% in DecemberOrganogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 11,000,000 shares, an increase of 29.1% from the November 30th total of 8,520,000 shares. Based on an average daily trading volume, of 690,900 shares, the short-interest ratio is currently 15.9 days. Approximately 16.3% of the company's stock are sold short.December 29, 2024 | marketbeat.comOrganogenesis files to sell 130K shares of common stock for holdersDecember 20, 2024 | markets.businessinsider.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells $19,491.65 in StockDecember 17, 2024 | insidertrades.comGary S. Gillheeney Sells 5,585 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) StockOrganogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) CEO Gary S. Gillheeney sold 5,585 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.49, for a total transaction of $19,491.65. Following the completion of the transaction, the chief executive officer now owns 3,039,194 shares of the company's stock, valued at $10,606,787.06. This trade represents a 0.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.December 16, 2024 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 55,615 SharesOrganogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) CEO Gary S. Gillheeney sold 55,615 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total transaction of $186,866.40. Following the completion of the sale, the chief executive officer now owns 3,044,779 shares of the company's stock, valued at approximately $10,230,457.44. The trade was a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.December 16, 2024 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 157,448 SharesDecember 13, 2024 | insidertrades.comInsider Selling: Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells 18,416 Shares of StockDecember 10, 2024 | insidertrades.comJacobs Levy Equity Management Inc. Sells 148,326 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)Jacobs Levy Equity Management Inc. decreased its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 34.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 281,478 shares of the company's stoDecember 10, 2024 | marketbeat.comAdvantage Alpha Capital Partners LP Trims Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)Advantage Alpha Capital Partners LP lessened its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 71.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 101,558 shares of the company's stock after selling 256November 27, 2024 | marketbeat.comOrganogenesis Expands Manufacturing Capacity to Support Future GrowthNovember 22, 2024 | globenewswire.comAnalysts Set Expectations for Organogenesis FY2024 EarningsOrganogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for Organogenesis in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of (November 18, 2024 | marketbeat.comMorgan Stanley Sticks to Their Hold Rating for Organogenesis Holdings (ORGO)November 15, 2024 | markets.businessinsider.comOrganogenesis ‘commends’ final local coverage determinationsNovember 15, 2024 | markets.businessinsider.comOrganogenesis (NASDAQ:ORGO) Announces Earnings Results, Beats Estimates By $0.11 EPSOrganogenesis (NASDAQ:ORGO - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.11. The company had revenue of $115.18 million during the quarter, compared to analysts' expectations of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period in the previous year, the business earned $0.02 earnings per share.November 15, 2024 | marketbeat.comOrganogenesis Commends Final LCDsNovember 15, 2024 | globenewswire.com Remove Ads Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address ORGO Media Mentions By Week ORGO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORGO News Sentiment▼0.750.85▲Average Medical News Sentiment ORGO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORGO Articles This Week▼42▲ORGO Articles Average Week Remove Ads Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Recursion Pharmaceuticals News Twist Bioscience News Bausch Health Companies News NewAmsterdam Pharma News HUTCHMED News MoonLake Immunotherapeutics News ImmunityBio News Beam Therapeutics News Vericel News Mirum Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORGO) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
